Inovio Pharmaceuticals (INO) Competitors $1.43 +0.01 (+0.70%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.44 +0.02 (+1.05%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INO vs. MRNA, MGRM, PTHL, CV, INGN, SGHT, TLSI, PROF, PDEX, and KRMDShould you be buying Inovio Pharmaceuticals stock or one of its competitors? The main competitors of Inovio Pharmaceuticals include Moderna (MRNA), Monogram Orthopaedics (MGRM), Pheton (PTHL), CapsoVision (CV), Inogen (INGN), Sight Sciences (SGHT), TriSalus Life Sciences (TLSI), Profound Medical (PROF), Pro-Dex (PDEX), and KORU Medical Systems (KRMD). Inovio Pharmaceuticals vs. Its Competitors Moderna Monogram Orthopaedics Pheton CapsoVision Inogen Sight Sciences TriSalus Life Sciences Profound Medical Pro-Dex KORU Medical Systems Moderna (NASDAQ:MRNA) and Inovio Pharmaceuticals (NASDAQ:INO) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk. Which has better valuation and earnings, MRNA or INO? Inovio Pharmaceuticals has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioModerna$3.24B3.30-$3.56B-$8.73-3.16Inovio Pharmaceuticals$220K238.36-$107.25M-$3.19-0.45 Which has more volatility & risk, MRNA or INO? Moderna has a beta of 1.83, suggesting that its stock price is 83% more volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500. Is MRNA or INO more profitable? Inovio Pharmaceuticals has a net margin of 0.00% compared to Moderna's net margin of -105.67%. Moderna's return on equity of -28.69% beat Inovio Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Moderna-105.67% -28.69% -21.94% Inovio Pharmaceuticals N/A -136.93%-89.99% Do analysts recommend MRNA or INO? Moderna presently has a consensus target price of $46.11, indicating a potential upside of 67.07%. Inovio Pharmaceuticals has a consensus target price of $8.80, indicating a potential upside of 515.38%. Given Inovio Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Inovio Pharmaceuticals is more favorable than Moderna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moderna 4 Sell rating(s) 17 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.04Inovio Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 Does the media prefer MRNA or INO? In the previous week, Moderna had 45 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 45 mentions for Moderna and 0 mentions for Inovio Pharmaceuticals. Moderna's average media sentiment score of 0.26 beat Inovio Pharmaceuticals' score of 0.00 indicating that Moderna is being referred to more favorably in the media. Company Overall Sentiment Moderna Neutral Inovio Pharmaceuticals Neutral Do institutionals and insiders believe in MRNA or INO? 75.3% of Moderna shares are owned by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. 11.0% of Moderna shares are owned by company insiders. Comparatively, 2.3% of Inovio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryModerna beats Inovio Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get Inovio Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INO vs. The Competition Export to ExcelMetricInovio PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$52.44M$3.02B$5.53B$9.37BDividend YieldN/A2.44%4.74%4.12%P/E Ratio-0.4517.6228.8823.79Price / Sales238.36309.96440.8796.30Price / CashN/A41.6335.0757.18Price / Book0.758.488.255.54Net Income-$107.25M-$55.06M$3.25B$259.88M7 Day Performance-2.72%-3.99%-3.75%-4.67%1 Month Performance-33.18%9.58%4.27%4.40%1 Year Performance-84.93%6.70%25.83%17.91% Inovio Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INOInovio Pharmaceuticals3.169 of 5 stars$1.43+0.7%$8.80+515.4%-85.7%$52.44M$220K-0.45320Upcoming EarningsGap DownMRNAModerna4.4664 of 5 stars$33.91-0.7%$46.11+36.0%-70.7%$13.21B$3.24B0.005,800Trending NewsEarnings ReportAnalyst ForecastOptions VolumeGap DownMGRMMonogram Orthopaedics1.3226 of 5 stars$5.69+0.2%$5.40-5.1%+128.4%$202.71M$370K0.0028News CoveragePTHLPhetonN/A$30.96+6.2%N/AN/A$191.87M$450K0.0011News CoveragePositive NewsCVCapsoVisionN/A$4.35+8.8%$5.50+26.4%N/A$185.38MN/A0.0090News CoveragePositive NewsAnalyst RevisionINGNInogen4.2073 of 5 stars$6.79-0.1%$11.00+62.0%-31.8%$182.83M$335.70M-5.901,030Upcoming EarningsSGHTSight Sciences2.083 of 5 stars$3.54+1.4%$3.93+11.1%-55.9%$180.42M$79.87M0.00210TLSITriSalus Life Sciences2.2014 of 5 stars$4.55-0.2%$10.75+136.3%-27.9%$172.55M$29.43M0.00106PROFProfound Medical1.8241 of 5 stars$5.70+0.4%$11.00+93.0%-48.1%$170.70M$10.68M-4.67150Upcoming EarningsPDEXPro-Dex2.3368 of 5 stars$53.50+8.2%$56.00+4.7%+133.1%$161.19M$53.84M19.11140News CoverageHigh Trading VolumeKRMDKORU Medical Systems2.5239 of 5 stars$3.41-1.4%$4.63+35.6%+50.0%$159.65M$33.65M0.0080News CoverageUpcoming Earnings Related Companies and Tools Related Companies Moderna Alternatives Monogram Orthopaedics Alternatives Pheton Alternatives CapsoVision Alternatives Inogen Alternatives Sight Sciences Alternatives TriSalus Life Sciences Alternatives Profound Medical Alternatives Pro-Dex Alternatives KORU Medical Systems Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INO) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredStrange twist to Bitcoin’s rallyThe #1 crypto to buy today Better than Bitcoin? (top crypto for less than $1) Over the past 15 years, B...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inovio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inovio Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
